DOCSLIB.ORG

Hawaii Medicaid Fee Schedule 200711

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hawaii Medicaid Fee Schedule 200711 Medicaid Fee PROC-CD MOD Description Schedule 10021 FINE NEEDLE ASPIRATION; WITHOUT IMAGING GUIDANCE $65.06 10022 FINE NEEDLE ASPIRATION; WITH IMAGING GUIDANCE $66.30 10040 ACNE SURGERY (EG, MARSUPIALIZATION, OPENING OR REMOVAL OF $47.83 10040 32 ACNE SURGERY (EG, MARSUPIALIZATION, OPENING OR REMOVAL OF $62.24 10060 INCISION AND DRAINAGE OF ABSCESS (EG, CARBUNCLE, SUPPURATIVE $52.42 10060 32 INCISION AND DRAINAGE OF ABSCESS (EG, CARBUNCLE, SUPPURATIVE $59.93 10061 INCISION AND DRAINAGE OF ABSCESS (EG, CARBUNCLE, SUPPURATIVE $97.47 10061 32 INCISION AND DRAINAGE OF ABSCESS (EG, CARBUNCLE, SUPPURATIVE $108.08 10080 32 INCISION AND DRAINAGE OF PILONIDAL CYST $107.30 10080 INCISION AND DRAINAGE OF PILONIDAL CYST $56.78 10081 32 INCISION AND DRAINAGE OF PILONIDAL CYST $163.42 10081 INCISION AND DRAINAGE OF PILONIDAL CYST $103.48 10120 32 INCISION AND REMOVAL OF FOREIGN BODY, SUBCUTANEOUS TISSUES $85.13 10120 INCISION AND REMOVAL OF FOREIGN BODY, SUBCUTANEOUS TISSUES $54.57 10121 32 INCISION AND REMOVAL OF FOREIGN BODY, SUBCUTANEOUS TISSUES $156.40 10121 INCISION AND REMOVAL OF FOREIGN BODY, SUBCUTANEOUS TISSUES $112.70 10140 32 INCISION AND DRAINAGE OF HEMATOMA $83.39 10140 INCISION AND DRAINAGE OF HEMATOMA $71.01 10160 PUNCTURE ASPIRATION OF ABSCESS, HEMATOMA, BULLA, OR CYST $57.25 10160 32 PUNCTURE ASPIRATION OF ABSCESS, HEMATOMA, BULLA, OR CYST $70.39 10180 32 INCISION AND DRAINAGE, COMPLEX, POSTOPERATIVE WOUND INFECTION $133.32 10180 INCISION AND DRAINAGE, COMPLEX, POSTOPERATIVE WOUND INFECTION $108.05 11000 32 DEBRIDEMENT OF EXTENSIVE ECZEMATOUS OR INFECTED SKIN $31.76 11000 DEBRIDEMENT OF EXTENSIVE ECZEMATOUS OR INFECTED SKIN $23.96 11001 DEBRIDEMENT OF EXTENSIVE ECZEMATOUS OR INFECTED SKIN $12.45 11001 32 DEBRIDEMENT OF EXTENSIVE ECZEMATOUS OR INFECTED SKIN $17.44 DEBRIDEMENT OF SKIN, SUBCUTANEOUS TISSUE, MUSCLE AND FASCIA 11004 FOR NECROTIZING $415.20 DEBRIDEMENT OF SKIN, SUBCUTANEOUS TISSUE, MUSCLE AND FASCIA 11005 FOR NECROTIZING $566.13 DEBRIDEMENT OF SKIN, SUBCUTANEOUS TISSUE, MUSCLE AND FASCIA 11006 FOR NECROTIZING $520.32 REMOVAL OF PROSTHETIC MATERIAL OR MESH, ABDOMINAL WALL FOR 11008 NECROTIZING SOFT $211.51 DEBRIDEMENT INCLUDING REMOVAL OF FOREIGN MATERIAL 11010 32 ASSOCIATEDWITH OPEN FRACTURE $281.81 DEBRIDEMENT INCLUDING REMOVAL OF FOREIGN MATERIAL 11010 ASSOCIATEDWITH OPEN FRACTURE $219.04 DEBRIDEMENT INCLUDING REMOVAL OF FOREIGN MATERIAL ASSOC 11011 32 WITHOPEN FX(S)/DISLOCATI $333.00 DEBRIDEMENT INCLUDING REMOVAL OF FOREIGN MATERIAL ASSOC 11011 WITHOPEN FX(S)/DISLOCATI $262.37 DEBRIDEMENT INCLUDING REMOVAL OF FOREIGN MATERIAL ASSOC 11012 32 WITHOPEN FRACTURE(S)/DIS $484.78 DEBRIDEMENT INCLUDING REMOVAL OF FOREIGN MATERIAL ASSOC 11012 WITHOPEN FRACTURE(S)/DIS $373.19 11040 32 DEBRIDEMENT $27.63 11040 DEBRIDEMENT $20.46 11041 DEBRIDEMENT $33.06 11041 32 DEBRIDEMENT $42.11 11042 32 DEBRIDEMENT $56.05 11042 DEBRIDEMENT $44.20 11043 32 DEBRIDEMENT $145.85 11043 DEBRIDEMENT $125.89 11044 DEBRIDEMENT $172.73 11044 32 DEBRIDEMENT $190.42 Medicaid Fee Schedule 200711 Draft 1 Medicaid Fee PROC-CD MOD Description Schedule PARING OR CUTTING OF BENIGN HYPERKERATOTIC LESION (EG, CORN OR 11055 32 CALLUS); SINGLE L $24.88 PARING OR CUTTING OF BENIGN HYPERKERATOTIC LESION (EG, CORN OR 11055 CALLUS); SINGLE L $15.03 PARING OR CUTTING OF BENIGN HYPERKERATOTIC LESION (EG, CORN OR 11056 32 CALLUS); TWO TO F $31.38 PARING OR CUTTING OF BENIGN HYPERKERATOTIC LESION (EG, CORN OR 11056 CALLUS); TWO TO F $21.02 PARING OR CUTTING OF BENIGN HYPERKERATOTIC LESION (EG, CORN OR 11057 32 CALLUS); MORE THA $38.57 PARING OR CUTTING OF BENIGN HYPERKERATOTIC LESION (EG, CORN OR 11057 CALLUS); MORE THA $27.45 11100 32 BIOPSY OF SKIN, SUBCUTANEOUS TISSUE AND/OR MUCOUS MEMBRANE $54.75 11100 BIOPSY OF SKIN, SUBCUTANEOUS TISSUE AND/OR MUCOUS MEMBRANE $32.61 11101 BIOPSY OF SKIN, SUBCUTANEOUS TISSUE AND/OR MUCOUS MEMBRANE $16.91 11101 32 BIOPSY OF SKIN, SUBCUTANEOUS TISSUE AND/OR MUCOUS MEMBRANE $26.88 11200 EXCISION (INCLUDING SIMPLE CLOSURE OR LIGATURE STRANGULATION), $37.52 11200 32 EXCISION (INCLUDING SIMPLE CLOSURE OR LIGATURE STRANGULATION), $44.96 11201 EXCISION (INCLUDING SIMPLE CLOSURE OR LIGATURE STRANGULATION), $11.56 11201 32 EXCISION (INCLUDING SIMPLE CLOSURE OR LIGATURE STRANGULATION), $17.49 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, TRUNK, 11300 32 ARMS OR LEGS; LESIO $38.81 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, TRUNK, 11300 ARMS OR LEGS; LESIO $22.28 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, TRUNK, 11301 32 ARMS OR LEGS; LESIO $52.06 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, TRUNK, 11301 ARMS OR LEGS; LESIO $35.53 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, TRUNK, 11302 32 ARMS OR LEGS; LESIO $62.88 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, TRUNK, 11302 ARMS OR LEGS; LESIO $44.16 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, TRUNK, 11303 32 ARMS OR LEGS; LESIO $77.80 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, TRUNK, 11303 ARMS OR LEGS; LESIO $54.40 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, SCALP, 11305 32 NECK, HANDS, FEET, $39.84 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, SCALP, 11305 NECK, HANDS, FEET, $27.37 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, SCALP, 11306 32 NECK, HANDS, FEET, $55.68 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, SCALP, 11306 NECK, HANDS, FEET, $40.09 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, SCALP, 11307 32 NECK, HANDS, FEET, $65.24 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, SCALP, 11307 NECK, HANDS, FEET, $47.15 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, SCALP, 11308 32 NECK, HANDS, FEET, $81.58 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, SCALP, 11308 NECK, HANDS, FEET, $60.37 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, FACE, EARS, 11310 32 EYELIDS, NOSE, $49.21 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, FACE, EARS, 11310 EYELIDS, NOSE, $31.44 Medicaid Fee Schedule 200711 Draft 2 Medicaid Fee PROC-CD MOD Description Schedule SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, FACE, EARS, 11311 32 EYELIDS, NOSE, $62.25 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, FACE, EARS, 11311 EYELIDS, NOSE, $44.16 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, FACE, EARS, 11312 32 EYELIDS, NOSE, $71.81 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, FACE, EARS, 11312 EYELIDS, NOSE, $51.54 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, FACE, EARS, 11313 32 EYELIDS, NOSE, $93.59 SHAVING OF EPIDERMAL OR DERMAL LESION, SINGLE LESION, FACE, EARS, 11313 EYELIDS, NOSE, $69.27 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11400 ELSEWHERE), $42.74 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11400 32 ELSEWHERE), $71.86 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11401 ELSEWHERE), $56.58 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11401 32 ELSEWHERE), $85.90 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11402 ELSEWHERE), $67.58 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11402 32 ELSEWHERE), $99.08 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11403 ELSEWHERE), $81.11 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11403 32 ELSEWHERE), $116.04 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11404 ELSEWHERE), $92.35 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11404 32 ELSEWHERE), $130.08 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11406 32 ELSEWHERE), $159.67 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11406 ELSEWHERE), $132.54 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11420 ELSEWHERE), $47.53 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11420 32 ELSEWHERE), $69.19 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11421 ELSEWHERE), $64.22 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11421 32 ELSEWHERE), $90.73 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11422 ELSEWHERE), $73.76 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11422 32 ELSEWHERE), $103.59 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11423 ELSEWHERE), $91.62 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11423 32 ELSEWHERE), $126.55 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11424 ELSEWHERE), $107.64 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11424 32 ELSEWHERE), $142.88 Medicaid Fee Schedule 200711 Draft 3 Medicaid Fee PROC-CD MOD Description Schedule EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11426 32 ELSEWHERE), $194.19 EXCISION, BENIGN LESION, EXCEPT SKIN TAG (UNLESS LISTED 11426 ELSEWHERE), $167.69 11440 EXCISION, OTHER BENIGN LESION (UNLESS LISTED ELSEWHERE), FACE, $58.77 11440 32 EXCISION, OTHER BENIGN LESION (UNLESS LISTED ELSEWHERE), FACE, $83.10 11441 EXCISION, OTHER BENIGN LESION (UNLESS LISTED ELSEWHERE), FACE, $73.83 11441 32 EXCISION, OTHER BENIGN LESION (UNLESS LISTED ELSEWHERE), FACE, $100.32 11442 EXCISION, OTHER BENIGN LESION (UNLESS LISTED ELSEWHERE), FACE, $81.88 11442 32 EXCISION, OTHER BENIGN LESION (UNLESS LISTED ELSEWHERE), FACE, $113.28 11443 EXCISION, OTHER BENIGN LESION (UNLESS LISTED ELSEWHERE), FACE, $106.21 11443 32 EXCISION, OTHER BENIGN LESION (UNLESS LISTED ELSEWHERE), FACE, $143.63 11444 EXCISION, OTHER BENIGN LESION (UNLESS LISTED ELSEWHERE), FACE, $138.99 11444 32 EXCISION, OTHER BENIGN LESION (UNLESS LISTED ELSEWHERE), FACE, $177.35 11446 EXCISION, OTHER BENIGN LESION (UNLESS LISTED ELSEWHERE), FACE, $180.43 11446 32 EXCISION, OTHER BENIGN LESION (UNLESS
Load more

Recommended publications
  • Gastrostomy Feeding Tubes
    Gastrostomy feeding tubes With Dr Anastasia Volovets, Gastroenterologist and Hepatologist, Royal Prince Alfred Hospital, Sydney, Australia Introduction In patients with prolonged inadequate or absent oral intake gastrostomy tubes can be used to provide a route for enteral feeding, hydration, and medication administration. Case 1 - You are a junior doctor on the wards and you’re called to see a 65 year old male, who is day 5 post- stroke with an impaired swallow he is unable to tolerate oral feed and his family is worried he will starve to death. 1. Management of this patient IV fluids do not provide the caloric support or nutrients needed by patients, after 48 hours of impaired oral feeding, enteral feeding should be considered. • Short term this would be a nasogastric tube • Longer term (greater than 6 weeks) a gastrostomy or jejunostomy should be considered 2. Indications for enteral feeding • Neurological disorders causing impaired swallowing and aspiration of food o Stroke (most common) o Traumatic brain injury o Parkinson’s disease • Structural problems o Malignancy obstructing the gastrointestinal tract, this can include upper GI, head, nose or throat. Gastrostomy insertion can be done prophylactically prior to treatment that will impair the functioning or path of the tract such as surgery or radiotherapy 3. Contraindications to gastric feeding tubes • Absolute o High bleeding risk - uncorrected coagulopathy, thrombocytopenia o Chronic liver disease - varies and ascites o Peritonitis or abdominal perforation o Cellulitis at selected
    [Show full text]
  • What Is Optical Imaging?
    What is Optical Imaging? Optical imaging uses light to interrogate cellular and molecular function in the living body, as well as in animal and plant tissue. The information is ultimately derived from tissue composition and biomolecular processes. Images are generated by using photons of light in the wavelength range from ultraviolet to near infrared. Contrast is derived through the use of: exogenous agents (i.e., dyes or probes) that provide a signal endogenous molecules with optical signatures (i.e., NADH, hemoglobin, collagens, etc.) reporter genes. Florescence Imaging Fluorescence protein imaging uses endogenous or exogenous molecules or materials that emit light when activated by an external light source such as a laser. An external light of appropriate wavelength is used to excite a target molecule, which then fluoresces by releasing longer-wavelength, lower-energy light. Fluorescence imaging provides the ability to localize and measure gene expression including normally expressed and aberrant genes, proteins and other pathophysiologic processes. Other potential uses include cell trafficking, tagging superficial structures, detecting lesions and for monitoring tumor growth and response to therapy. Bioluminescent Imaging (BLI) Bioluminescent imaging uses a natural light-emitting protein such as luciferase to trace the movement of certain cells or to identify the location of specific chemical reactions within the body. Bioluminescent imaging is being applied to both gene expression and therapeutic monitoring. Optical Imaging Technologies Near-infrared fluorescence imaging involves imaging fluorescence photons in the near-infrared range (typically 600– 900 nm). A fluorochrome is excited by a lower wavelength, light source and the emitted excitation is recorded as a slightly higher wavelength with a high sensitivity charge-coupled-device (CCD) camera.
    [Show full text]
  • National Correct Coding Initiative Policy Manual for Medicare Services Revision Date: 1/1/2019
    National Correct Coding Initiative Policy Manual for Medicare Services Revision Date: 1/1/2019 Current Procedural Terminology (CPT) codes, descriptions and other data only are copyright 2018 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association. Applicable FARS\DFARS Restrictions Apply to Government Use. Fee schedules, relative value units, conversion factors, prospective payment systems, and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for the data contained or not contained herein. TABLE OF CONTENTS FOR NATIONAL CORRECT CODING INITIATIVE POLICY MANUAL FOR MEDICARE SERVICES Introduction Introduction Intro-3 Purpose Intro-3 Policy Manual Background Intro-6 Edit Development and Review Process Intro-7 Sources of Information about NCCI and MUE Intro-9 Correspondence to CMS about NCCI and its Contents Intro-10 Chapter I - General Correct Coding Policies List of Acronyms I-3 A. Introduction I-5 B. Coding Based on Standards of Medical/Surgical I-9 Practice C. Medical/Surgical Package I-12 D. Evaluation and Management (E&M) Services I-17 E. Modifiers and Modifier Indicators I-19 F. Standard Preparation/Monitoring Services for I-27 Anesthesia G. Anesthesia Service Included in the Surgical Procedure I-27 H. HCPCS/CPT Procedure Code Definition I-28 I. CPT Manual and CMS Coding Manual Instructions I-29 J. CPT “Separate Procedure” Definition I-30 K. Family of Codes I-30 L.
    [Show full text]
  • Tutankhamun's Dentition: the Pharaoh and His Teeth
    Brazilian Dental Journal (2015) 26(6): 701-704 ISSN 0103-6440 http://dx.doi.org/10.1590/0103-6440201300431 1Department of Oral and Maxillofacial Tutankhamun’s Dentition: Surgery, University Hospital of Leipzig, Leipzig, Germany The Pharaoh and his Teeth 2Institute of Egyptology/Egyptian Museum Georg Steindorff, University of Leipzig, Leipzig, Germany 3Department of Orthodontics, University Hospital of Greifswald, Greifswald, Germany Niels Christian Pausch1, Franziska Naether2, Karl Friedrich Krey3 Correspondence: Dr. Niels Christian Pausch, Liebigstraße 12, 04103 Leipzig, Germany. Tel: +49- 341-97-21160. e-mail: niels. [email protected] Tutankhamun was a Pharaoh of the 18th Dynasty (New Kingdom) in ancient Egypt. Medical and radiological investigations of his skull revealed details about the jaw and teeth status of the mummy. Regarding the jaw relation, a maxillary prognathism, a mandibular retrognathism and micrognathism have been discussed previously. A cephalometric analysis was performed using a lateral skull X-ray and a review of the literature regarding Key Words: Tutankhamun’s King Tutankhamun´s mummy. The results imply diagnosis of mandibular retrognathism. dentition, cephalometric analysis, Furthermore, third molar retention and an incomplete, single cleft palate are present. mandibular retrognathism Introduction also been discussed (11). In 1922, the British Egyptologist Howard Carter found the undisturbed mummy of King Tutankhamun. The Case Report spectacular discovery enabled scientists of the following In the evaluation of Tutankhamun’s dentition and jaw decades to analyze the Pharaoh's remains. The mummy alignment, contemporary face reconstructions and coeval underwent multiple autopsies. Until now, little was artistic images can be of further use. However, the ancient published about the jaw and dentition of the King.
    [Show full text]
  • Nasal Airflow Measured by Rhinomanometry Correlates with Feno in Children with Asthma
    RESEARCH ARTICLE Nasal Airflow Measured by Rhinomanometry Correlates with FeNO in Children with Asthma I-Chen Chen1☯, Yu-Tsai Lin2☯, Jong-Hau Hsu1,3, Yi-Ching Liu1, Jiunn-Ren Wu1,3, Zen- Kong Dai1,3* 1 Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, 2 Department of Otolaryngology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, 3 Department of Pediatrics, School of Medicine, College of Medicine, a11111 Kaohsiung Medical University, Kaohsiung, Taiwan ☯ These authors contributed equally to this work. * [email protected] Abstract OPEN ACCESS Citation: Chen I-C, Lin Y-T, Hsu J-H, Liu Y-C, Wu Background J-R, Dai Z-K (2016) Nasal Airflow Measured by Rhinitis and asthma share similar immunopathological features. Rhinomanometry is an Rhinomanometry Correlates with FeNO in Children with Asthma. PLoS ONE 11(10): e0165440. important test used to assess nasal function and spirometry is an important tool used in doi:10.1371/journal.pone.0165440 asthmatic children. The degree to which the readouts of these tests are correlated has yet Editor: Stelios Loukides, National and Kapodistrian to be established. We sought to clarify the relationship between rhinomanometry measure- University of Athens, GREECE ments, fractional exhaled nitric oxide (FeNO), and spirometric measurements in asthmatic Received: September 3, 2016 children. Accepted: October 11, 2016 Methods Published: October 28, 2016 Patients' inclusion criteria: age between 5 and 18 years, history of asthma with nasal symp- Copyright: © 2016 Chen et al. This is an open toms, and no anatomical deformities. All participants underwent rhinomanometric evalua- access article distributed under the terms of the Creative Commons Attribution License, which tions and pulmonary function and FeNO tests.
    [Show full text]
  • Diagnostic Nasal/Sinus Endoscopy, Functional Endoscopic Sinus Surgery (FESS) and Turbinectomy
    Medical Coverage Policy Effective Date ............................................. 7/10/2021 Next Review Date ....................................... 3/15/2022 Coverage Policy Number .................................. 0554 Diagnostic Nasal/Sinus Endoscopy, Functional Endoscopic Sinus Surgery (FESS) and Turbinectomy Table of Contents Related Coverage Resources Overview .............................................................. 1 Balloon Sinus Ostial Dilation for Chronic Sinusitis and Coverage Policy ................................................... 2 Eustachian Tube Dilation General Background ............................................ 3 Drug-Eluting Devices for Use Following Endoscopic Medicare Coverage Determinations .................. 10 Sinus Surgery Coding/Billing Information .................................. 10 Rhinoplasty, Vestibular Stenosis Repair and Septoplasty References ........................................................ 28 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence
    [Show full text]
  • Fearful Symmetries: Essays and Testimonies Around Excision and Circumcision. Rodopi
    Fearful Symmetries Matatu Journal for African Culture and Society ————————————]^——————————— EDITORIAL BOARD Gordon Collier Christine Matzke Frank Schulze–Engler Geoffrey V. Davis Aderemi Raji–Oyelade Chantal Zabus †Ezenwa–Ohaeto TECHNICAL AND CARIBBEAN EDITOR Gordon Collier ———————————— ]^ ——————————— BOARD OF ADVISORS Anne V. Adams (Ithaca NY) Jürgen Martini (Magdeburg, Germany) Eckhard Breitinger (Bayreuth, Germany) Henning Melber (Windhoek, Namibia) Margaret J. Daymond (Durban, South Africa) Amadou Booker Sadji (Dakar, Senegal) Anne Fuchs (Nice, France) Reinhard Sander (San Juan, Puerto Rico) James Gibbs (Bristol, England) John A. Stotesbury (Joensuu, Finland) Johan U. Jacobs (Durban, South Africa) Peter O. Stummer (Munich, Germany) Jürgen Jansen (Aachen, Germany) Ahmed Yerma (Lagos, Nigeria)i — Founding Editor: Holger G. Ehling — ]^ Matatu is a journal on African and African diaspora literatures and societies dedicated to interdisciplinary dialogue between literary and cultural studies, historiography, the social sciences and cultural anthropology. ]^ Matatu is animated by a lively interest in African culture and literature (including the Afro- Caribbean) that moves beyond worn-out clichés of ‘cultural authenticity’ and ‘national liberation’ towards critical exploration of African modernities. The East African public transport vehicle from which Matatu takes its name is both a component and a symbol of these modernities: based on ‘Western’ (these days usually Japanese) technology, it is a vigorously African institution; it is usually
    [Show full text]
  • Pancreaticogastrostomy
    eCommons@AKU Section of General Surgery Department of Surgery October 2017 Pancreaticogastrostomy - an alternate for dealing with pancreatic remnant after pancreaticoduodenectomy - experience from a tertiary care center of Pakistan Tabish Chawla Aga Khan University, [email protected] Hassaan Bari Aga Khan University Shahrukh Effendi Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_surg_gen Part of the Surgery Commons Recommended Citation Chawla, T., Bari, H., Effendi, S. (2017). Pancreaticogastrostomy - an alternate for dealing with pancreatic remnant after pancreaticoduodenectomy - experience from a tertiary care center of Pakistan. Journal of Pakistan Medical Association, 67(10), 1621-1624. Available at: https://ecommons.aku.edu/pakistan_fhs_mc_surg_gen/76 1621 CASE SERIES Pancreaticogastrostomy — an alternate for dealing with pancreatic remnant after pancreaticoduodenectomy — experience from a tertiary care center of Pakistan Tabish Chawla, Hassaan Bari, Shahrukh Effendi Abstract as part of PD. Therefore it was associated with high Whipple's pancreaticoduodenectomy has been refined morbidity and mortality resulting from high rates of over the years to be a safe operation though the leakage from pancreatic stump. morbidity rate still remains high (30-50%). Pancreatic Pancreatcogastrostomy is a repopularized technique fistula is the most important cause of mortality which has been described previously in literature. 3 This following pancreaticoduodenectomy. To prevent it, study was done to review the experience of PG being surgeons have used two anastomotic techniques: done as an alternate to PJ after PD. pancreaticojejunostomy and pancreaticogastrostomy. Recent studies found that pancreaticogastrostomy is Material and Methods associated with fewer overall complications than It is a case series collected at the Department of Surgery of pancreaticojejunostomy.
    [Show full text]
  • FAQ Document
    The Society of Thoracic Surgeons Frequently Asked Questions: General Thoracic Database Version 2.07 December 2008 How to use the “interactive” FAQ Document: 1. To review all clinical questions in an individual section, click on the section title below. Section A: seq# 10 - 190 Section C: seq# 285 - 650 Section E: seq# 770 - 1210 Section B: seq# 200 - 260 Section D: seq# 660 - 750 Section F: seq# 1220 - 1340 2. To review an individual Seq# clinical question, click on the Seq# title below. Participation in both General Thoracic and Adult Cardiac Databases GENERAL STATEMENT #2 Seq# 200: Zubrod Score Seq# 775: Postop Events Seq# 300: WtLoss3Kg Seq# 860: Pneumonia Seq# 310: Category of disease Seq# 930: Other Pulmonary Event Seq# 390: PreOp Chemotherapy Seq# 940: Atrial Arrhythmia Seq# 400: PreOp Thoracic RT Seq# 1020: Anastomotic leak Seq# 430: Other Cormorbidity Seq# 1190: Empyema Seq# 540: Clinical Stage Not Applicable (2.06) Seq# 1200: Other event req. Rx Seq# 725: Reoperation Seq# 1250: 30 Day Status Seq# 740: Procedure Seq# 1280: Chest Tube Out Date Seq# 750: Primary Procedure Seq# 751: Thoracoscopy Approach NEW Date SeqNo FieldName Definition 3/06 Participation in both General We participate in both Adult Cardiac and Yes, enter into both. In the Adult Cardiac DB, the Thoracic and Adult Cardiac General Thoracic Database. Our question primary procedure would be Seq# 1310 pertains to whether the patient should end up OpOCard=Yes; Seq# 2510 ONCAoAn=Yes; Databases in both databases. Scenario--We had a Seq# 2530 ONCArch=Yes; Seq# 2540 patient who had an aortic aneurysm repair ONCDesc=Yes; Seq# 3220 Readm30=Yes; (arch/descending thoracic) and was entered Seq# ReadmRsn=either Pneumonia or other into the Adult Cardiac Database.
    [Show full text]
  • High Risk Percutaneous Endoscopic Gastrostomy Tubes: Issues to Consider
    NUTRITIONINFLAMMATORY ISSUES BOWEL IN GASTROENTEROLOGY, DISEASE: A PRACTICAL SERIES APPROACH, #105 SERIES #73 Carol Rees Parrish, M.S., R.D., Series Editor High Risk Percutaneous Endoscopic Gastrostomy Tubes: Issues to Consider Iris Vance Neeral Shah Percutaneous endoscopy gastrostomy (PEG) tubes are a valuable tool for providing long- term enteral nutrition or gastric decompression; certain circumstances that complicate PEG placement warrant novel approaches and merit review and discussion. Ascites and portal hypertension with varices have been associated with poorer outcomes. Bleeding is one of the most common serious complications affecting approximately 2.5% of all procedures. This article will review what evidence exists in these high risk scenarios and attempt to provide more clarity when considering these challenging clinical circumstances. INTRODUCTION ince the first Percutaneous Endoscopic has been found by multiple authors to portend a poor Gastrostomy tube was placed in 1979 (1), they prognosis in PEG placement (3,4, 5,6,7,8). This review Shave become an invaluable tool for providing will endeavor to provide more clarity when considering long-term enteral nutrition (EN) and are commonly used these challenging clinical circumstances. in patients with dysphagia following stroke, disabling motor neuron diseases such as multiple sclerosis and Ascites & Gastric Varices amyotrophic lateral sclerosis, and in those with head The presence of ascites is frequently viewed as a and neck cancer.They are also used for patients with relative, if not absolute, contraindication to PEG prolonged mechanical intubation, as well as gastric placement. Ascites adds technical difficulties and the decompression in those with severe gastroparesis, risk for potential complications (see Table 1).
    [Show full text]
  • Loss of Correction in Cubitus Varus Deformity After Osteotomy
    Loss of correction in cubitus varus deformity after osteotomy Chao You Shenzhen children's hospital Yibiao Zhou Shenzhen children's hospital https://orcid.org/0000-0001-9754-1089 Jingming Han ( [email protected] ) Research article Keywords: cubitus varus osteotomy Loss of correction Posted Date: May 5th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-26279/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/14 Abstract Purpose Cubitus varus deformity in the pediatric population is an infrequent but clinically important disease to orthopedic surgeons. Since these patient populations are different in many respects, we sought out to investigate the rates of loss of correction over time as well as the factors associated with loss of correction in pediatric patients undergoing osteotomy for treatment of cubitus varus deformity. Methods Between 2008-7 and 2017-7, we treated 30 cases of cubital varus had underwent the the osteotomy. We compared preoperative and postoperative clinical and imaging parameters (H-cobb angle,Baumman angle) for all patients. Postoperative evaluation was performed by telephone interview. Results In our study,there were 30 patients,included 17 males and 13 females.the mean age was 75 months old.In the rst follow-up,Approximately 80 % of patients had a loss of correction of H-cobband 83% of patients at the second follow-up. The Baumann angle also had a loss of correction,about 57% was lost at the rst follow-up,and 43% was lost at the second follow-up. The average interval between the rst follow-up and the second follow-up was 24 days The H-cobb angle mean loss was 2.4°.There was a statistically signicant difference between the H-cobb angle measured before surgery and the angle measured after surgery (p <0.05).
    [Show full text]
  • Aguide to Evidence-Based Practices
    A GUIDE TO EVIDENCE-BASED PRACTICES for INDIVIDUALS WITH DEVELOPMENTAL DISABILITIES This report was produced with the support of the Saginaw County Community Mental Health Authority May 2009 Compiled by Barbara Glassheim This document may not be reproduced or distributed without the express permission of SCCMHA A GUIDE TO EVIDENCE-BASED PRACTICES FOR INDIVIDUALS WITH DEVELOPMENTAL DISABILITIES V. 1.0 TABLE OF CONTENTS FORWARD ............................................................................................................... 1 EXECUTIVE SUMMARY ............................................................................................. 2 INTRODUCTION ....................................................................................................... 4 AN OVERVIEW OF EVIDENCE-BASED PRACTICE CONCEPTS ........................................... 7 CULTURAL CONSIDERATIONS ................................................................................. 10 MALTREATMENT ................................................................................................ 10 WOMEN ............................................................................................................. 11 OLDER ADULTS .................................................................................................. 11 ETHNIC GROUPS ................................................................................................ 12 DEAF CULTURE .................................................................................................. 13 EMPOWERMENT
    [Show full text]